Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
Methodological detailsmultidisciplinary expert group
- Multidisciplinary expert group
Recommendations
As issued by the authors
Guidance covers baseline work-up and initiation of systemic therapy, relevance of symptoms, multidisciplinary assessment and patient education
Practical information on starting dose of lenvatinib, follow-up and monitoring, management of adverse events, and discontinuation and reinitiating of therapy
The importance of patient engagement is stressed
Original publication
Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice. Eur Thyroid J. Published 8 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →